Checkpoint Therapeutics (CKPT) Short Interest Ratio & Short Volume $4.18 +0.02 (+0.36%) As of 02:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Checkpoint Therapeutics Short Interest DataCheckpoint Therapeutics (CKPT) has a short interest of 3.80 million shares, representing 5.89% of the float (the number of shares available for trading by the public). This marks a -18.63% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.5, indicating that it would take 1.5 days of the average trading volume of 1.26 million shares to cover all short positions.Current Short Interest3,800,000 sharesPrevious Short Interest4,670,000 sharesChange Vs. Previous Month-18.63%Dollar Volume Sold Short$15.62 millionShort Interest Ratio1.5 Days to CoverLast Record DateApril 30, 2025Outstanding Shares83,764,000 sharesFloat Size64,480,000 sharesShort Percent of Float5.89%Today's Trading Volume394,843 sharesAverage Trading Volume1,259,574 sharesToday's Volume Vs. Average31% Short Selling Checkpoint Therapeutics? Sign up to receive the latest short interest report for Checkpoint Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartCKPT Short Interest Over TimeCKPT Days to Cover Over TimeCKPT Percentage of Float Shorted Over Time Checkpoint Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/30/20253,800,000 shares $15.62 million -18.6%5.9%1.5 $4.11 4/15/20254,670,000 shares $18.77 million -7.2%7.2%1.8 $4.02 3/31/20255,030,000 shares $20.32 million -1.6%8.1%2 $4.04 3/15/20255,110,000 shares $20.29 million -28.5%14.2%2.1 $3.97 2/28/20257,150,000 shares $20.45 million -4.5%19.9%3.2 $2.86 2/15/20257,490,000 shares $24.79 million -3.5%20.8%5.7 $3.31 1/31/20257,760,000 shares $22.04 million -2.1%21.7%5.8 $2.84 1/15/20257,930,000 shares $26.41 million -0.9%21.0%5.5 $3.33 12/31/20248,000,000 shares $25.60 million +17.5%21.1%5.7 $3.20 12/15/20246,810,000 shares $24.99 million +3.7%16.9%5.2 $3.67 Get the Latest News and Ratings for CKPT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Checkpoint Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 11/30/20246,570,000 shares $28.84 million +9.0%16.2%8.1 $4.39 11/15/20246,030,000 shares $20.68 million +8.5%14.9%8.3 $3.43 10/31/20245,560,000 shares $19.13 million +20.6%14.9%9.1 $3.44 10/15/20244,610,000 shares $12.17 million +5.3%12.3%10 $2.64 9/30/20244,380,000 shares $9.81 million +2.1%11.7%11 $2.24 9/15/20244,290,000 shares $9.87 million +4.9%11.4%10.9 $2.30 8/31/20244,090,000 shares $9.61 million -4.0%10.9%10.6 $2.35 8/15/20244,260,000 shares $9.50 million +0.7%11.8%11.3 $2.23 7/31/20244,230,000 shares $10.11 million +7.4%13.9%10 $2.39 7/15/20243,940,000 shares $9.89 million +2.9%13.0%10.1 $2.51 6/30/20243,830,000 shares $8.23 million +0.3%12.6%10.3 $2.15 6/15/20243,820,000 shares $8.10 million -6.1%13.1%10.1 $2.12 5/31/20244,070,000 shares $7.73 million +2.5%13.9%11.1 $1.90 5/15/20243,970,000 shares $6.47 million +12.8%12.7%9.8 $1.63 4/30/20243,520,000 shares $4.89 million -6.9%11.5%8.9 $1.39 4/15/20243,780,000 shares $6.50 million +1.1%12.4%7.9 $1.72 3/31/20243,740,000 shares $7.67 million +1.9%12.2%6.9 $2.05 3/15/20243,670,000 shares $7.05 million +9.6%18.2%5.6 $1.92 2/29/20243,350,000 shares $7.00 million -2.9%16.6%3.7 $2.09 2/15/20243,450,000 shares $6.93 million +0.6%17.1%3.7 $2.01 1/31/20243,430,000 shares $7.00 million -9.0%17.0%3.8 $2.04 1/15/20243,770,000 shares $7.31 million -7.4%18.7%4.6 $1.94 12/31/20234,070,000 shares $9.32 million +0.3%20.2%5.5 $2.29 12/15/20234,060,000 shares $13.48 million +28.1%19.9%6.1 $3.32 11/30/20233,170,000 shares $8.43 million +19.6%15.7%8.2 $2.66 11/15/20232,650,000 shares $4.98 million +10.9%13.1%10 $1.88 10/31/20232,390,000 shares $4.45 million +10.7%12.9%8.8 $1.86 10/15/20232,160,000 shares $4.04 million +19.3%11.7%7.2 $1.87 9/30/20231,810,000 shares $3.08 million +17.5%9.8%6.2 $1.70 9/15/20231,540,000 shares $3.03 million -2.5%8.6%5.9 $1.97Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/31/20231,580,000 shares $3.18 million +1.3%9.5%6.2 $2.01 8/15/20231,560,000 shares $3.15 million +6.1%9.4%5.8 $2.02 7/31/20231,470,000 shares $3.81 million +3.5%10.6%6 $2.59 7/15/20231,420,000 shares $3.82 million +3.7%11.9%6.9 $2.69 6/30/20231,370,000 shares $3.38 million +18.1%11.5%6.3 $2.47 6/15/20231,160,000 shares $3.20 million +11.5%9.1%3.7 $2.76 5/31/20231,040,000 shares $2.75 million +54.6%8.3%3.4 $2.64 5/15/2023672,900 shares $1.90 million +22.8%5.4%2.2 $2.83 4/30/2023548,200 shares $1.81 million +7.2%4.8%1.9 $3.30 4/15/2023511,300 shares $1.33 million -9.5%5.0%1.8 $2.61 3/31/2023564,900 shares $1.27 million +30.1%5.5%2 $2.25 3/15/2023434,200 shares $1.66 million +6.0%6.4%2.1 $3.82 2/28/2023409,500 shares $1.91 million +42.4%6.1%2.1 $4.67 2/15/2023287,600 shares $1.48 million +4.1%4.3%1.7 $5.14 1/31/2023276,300 shares $1.38 million -3.9%4.1%1.8 $4.98 1/15/2023287,500 shares $2.19 million -13.3%4.3%2.2 $7.60 12/30/2022331,700 shares $1.69 million -39.9%4.6%3.5 $5.11 12/15/2022552,200 shares $2.21 million +74.0%7.7%10.7 $4.00 11/30/2022317,400 shares $187,234.26 -90.1%N/A7.8 $0.59 11/15/20223,220,000 shares $2.43 million +4.2%4.5%11.5 $0.76 10/31/20223,090,000 shares $3.09 million -1.3%4.3%10.8 $1.00 10/15/20223,130,000 shares $3.12 million -2.2%4.4%10.5 $1.00 9/30/20223,200,000 shares $3.33 million +1.0%N/A10 $1.04 9/15/20223,170,000 shares $4.03 million -3.4%N/A9.5 $1.27 8/31/20223,280,000 shares $4.23 million -0.3%N/A8.5 $1.29 8/15/20223,290,000 shares $4.84 million -8.4%N/A7.7 $1.47 7/31/20223,590,000 shares $4.02 million +14.7%N/A7.3 $1.12 7/15/20223,130,000 shares $3.41 million +1.0%N/A6.4 $1.09 6/30/20223,100,000 shares $3.19 million -4.6%N/A5.4 $1.03 6/15/20223,250,000 shares $3.51 million -4.1%N/A5.3 $1.08 5/31/20223,390,000 shares $4.81 million -1.7%N/A4.8 $1.42 5/15/20223,450,000 shares $4.42 million +0.6%N/A4 $1.28 4/30/20223,430,000 shares $4.32 million +3.0%4.9%3.8 $1.26 4/15/20223,330,000 shares $4.80 million -29.5%4.8%2.2 $1.44 3/31/20224,720,000 shares $8.35 million -4.8%6.8%3 $1.77 3/15/20224,960,000 shares $8.38 million +37.0%7.7%3.3 $1.69 2/28/20223,620,000 shares $6.48 million +6.2%5.6%2.4 $1.79 2/15/20223,410,000 shares $7.40 million -21.6%5.3%2.3 $2.17 1/31/20224,350,000 shares $11.01 million +19.8%6.8%2.9 $2.53 1/15/20223,630,000 shares $9.47 million +22.6%N/A2.5 $2.61 12/31/20212,960,000 shares $9.21 million +11.3%4.6%3.3 $3.11 12/15/20212,660,000 shares $7.71 million +4.7%4.1%3.1 $2.90 11/30/20212,540,000 shares $7.52 million +25.1%3.9%3 $2.96 11/15/20212,030,000 shares $8.02 million +18.7%3.1%2.5 $3.95 10/29/20211,710,000 shares $6.00 million -1.2%2.7%2.4 $3.51 10/15/20211,730,000 shares $5.74 million No Change2.7%2.9 $3.32 9/30/20211,730,000 shares $5.71 million -3.4%2.7%2.5 $3.30 9/15/20211,790,000 shares $5.67 million -25.7%2.8%2.1 $3.17 8/31/20212,410,000 shares $7.76 million +0.8%3.8%2.4 $3.22 8/13/20212,390,000 shares $6.52 million -4.8%3.8%1.8 $2.73Think NVDA’s run was epic? You ain’t seen nothin’ yet (Ad)Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 7/30/20212,510,000 shares $6.60 million +4.6%4.0%1.8 $2.63 7/15/20212,400,000 shares $6.65 million +20.6%4.0%1.6 $2.77 6/30/20211,990,000 shares $5.87 million -58.8%3.3%1.4 $2.95 6/15/20214,830,000 shares $13.62 million +45.1%8.0%3.7 $2.82 5/28/20213,330,000 shares $8.92 million +9.5%5.5%2.7 $2.68 5/14/20213,040,000 shares $7.24 million +3.1%N/A3 $2.38 4/30/20212,950,000 shares $8.73 million +8.5%N/A2.1 $2.96 4/15/20212,720,000 shares $7.97 million +12.9%N/A2 $2.93 3/31/20212,410,000 shares $7.37 million -7.0%N/A1.7 $3.06 3/15/20212,590,000 shares $9.07 million +19.4%N/A1.8 $3.50 2/26/20212,170,000 shares $7.10 million -8.4%N/A1.6 $3.27 2/12/20212,370,000 shares $9.86 million -3.3%N/A1.9 $4.16 1/29/20212,450,000 shares $7.94 million -8.2%N/A3.1 $3.24 1/15/20212,670,000 shares $9.00 million +30.2%N/A3.8 $3.37 12/31/20202,050,000 shares $5.49 million -3.3%N/A3.6 $2.68 12/15/20202,120,000 shares $5.24 million -0.5%N/A3.4 $2.47 11/30/20202,130,000 shares $5.05 million -3.6%N/A2.1 $2.37 11/15/20202,210,000 shares $5.50 million -7.9%N/A2.2 $2.49 10/30/20202,400,000 shares $5.66 million +8.1%N/A2.4 $2.36 10/15/20202,220,000 shares $5.88 million -5.1%N/A2.1 $2.65 9/30/20202,340,000 shares $6.27 million +5.4%N/A1.7 $2.68 9/15/20202,220,000 shares $8.68 million +25.4%N/A1.8 $3.91 8/31/20201,770,000 shares $3.86 million +18.8%N/A2.6 $2.18 8/14/20201,490,000 shares $3.07 million +31.9%N/A2.3 $2.06 7/31/20201,130,000 shares $2.54 million +26.9%N/A1.8 $2.25 7/15/2020890,200 shares $1.50 million -0.7%N/A1.4 $1.68 6/30/2020896,300 shares $1.79 million +33.6%N/A3.1 $2.00 6/15/2020670,700 shares $1.31 million -7.7%N/A2.6 $1.96 5/29/2020726,700 shares $1.61 million -10.9%N/A2.7 $2.21 CKPT Short Interest - Frequently Asked Questions What is Checkpoint Therapeutics' current short interest? Short interest is the volume of Checkpoint Therapeutics shares that have been sold short but have not yet been covered or closed out. As of April 30th, investors have sold 3,800,000 shares of CKPT short. 5.89% of Checkpoint Therapeutics' shares are currently sold short. Learn More on Checkpoint Therapeutics' current short interest. What is a good short interest ratio for Checkpoint Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CKPT shares currently have a short interest ratio of 2.0. Learn More on Checkpoint Therapeutics's short interest ratio. Which institutional investors are shorting Checkpoint Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Checkpoint Therapeutics: Jane Street Group LLC, Heights Capital Management Inc., and Equitec Proprietary Markets LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Checkpoint Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.89% of Checkpoint Therapeutics' floating shares are currently sold short. Is Checkpoint Therapeutics' short interest increasing or decreasing? Checkpoint Therapeutics saw a drop in short interest during the month of April. As of April 30th, there was short interest totaling 3,800,000 shares, a drop of 18.6% from the previous total of 4,670,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Checkpoint Therapeutics' float size? Checkpoint Therapeutics currently has issued a total of 83,764,000 shares. Some of Checkpoint Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Checkpoint Therapeutics currently has a public float of 64,480,000 shares. How does Checkpoint Therapeutics' short interest compare to its competitors? 5.89% of Checkpoint Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Checkpoint Therapeutics: ANI Pharmaceuticals, Inc. (9.19%), ARS Pharmaceuticals, Inc. (29.82%), 89bio, Inc. (11.86%), Amphastar Pharmaceuticals, Inc. (9.22%), Ocular Therapeutix, Inc. (8.15%), Aurinia Pharmaceuticals Inc. (9.26%), Wave Life Sciences Ltd. (8.59%), Gyre Therapeutics, Inc. (13.99%), Phibro Animal Health Co. (4.52%), Mineralys Therapeutics, Inc. (16.91%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Spotify Technology S.A. ($4.67 billion), Charter Communications, Inc. ($4.58 billion), Capital One Financial Co. ($4.47 billion), The Kroger Co. ($2.56 billion), Reddit, Inc. ($2.23 billion), Rivian Automotive, Inc. ($2.16 billion), Live Nation Entertainment, Inc. ($1.90 billion), SoFi Technologies, Inc. ($1.85 billion), Zscaler, Inc. ($1.75 billion), and Omnicom Group Inc. ($1.75 billion). View all of the most shorted stocks. What does it mean to sell short Checkpoint Therapeutics stock? Short selling CKPT is an investing strategy that aims to generate trading profit from Checkpoint Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Checkpoint Therapeutics? A short squeeze for Checkpoint Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CKPT, which in turn drives the price of the stock up even further. How often is Checkpoint Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CKPT, twice per month. The most recent reporting period available is April, 30 2025. More Short Interest Resources from MarketBeat Related Companies ANIP Short Interest SPRY Short Interest ETNB Short Interest AMPH Short Interest OCUL Short Interest AUPH Short Interest WVE Short Interest GYRE Short Interest PAHC Short Interest MLYS Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:CKPT) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Checkpoint Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Checkpoint Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CKPT Stock Free CKPT Stock Alerts